Wells Fargo
ADAP

Wells Fargo’s Adaptimmune Therapeutics ADAP Stock Holding History

Wells Fargo’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,700
Closed -$351 – 7098
2025
Q3 		$351 Sell
2,700
-46,200
-94% -$6.34K ﹤0.01% 6318
2025
Q2 		$11.7K Buy
48,900
+8,200
+20% +$2.19K ﹤0.01% 5911
2025
Q1 		$8.02K Sell
40,700
-23,267
-36% -$12K ﹤0.01% 5934
2024
Q4 		$34.5K Sell
63,967
-2,854
-4% -$2.08K ﹤0.01% 5602
2024
Q3 		$63.5K Buy
66,821
+3,149
+5% +$3.57K ﹤0.01% 5260
2024
Q2 		$62.1K Buy
63,672
+9,500
+18% +$10.4K ﹤0.01% 5210
2024
Q1 		$85.6K Sell
54,172
-2,005
-4% -$2.42K ﹤0.01% 4977
2023
Q4 		$44.5K Buy
56,177
+1,432
+3% +$807 ﹤0.01% 5319
2023
Q3 		$42.7K Sell
54,745
-5,492
-9% -$4.61K ﹤0.01% 5261
2023
Q2 		$55.7K Buy
60,237
+54,037
+872% +$64.4K ﹤0.01% 5384
2023
Q1 		$6.76K Hold
6,200
– – ﹤0.01% 5975
2022
Q4 		$9.05K Hold
6,200
– – ﹤0.01% 5588
2022
Q3 		$6K Hold
6,200
– – ﹤0.01% 5838
2022
Q2 		$10K Sell
6,200
-1,596
-20% -$2.74K ﹤0.01% 5736
2022
Q1 		$15K Buy
7,796
+2,445
+46% +$6.6K ﹤0.01% 6117
2021
Q4 		$20K Hold
5,351
– – ﹤0.01% 6327
2021
Q3 		$27K Sell
5,351
-10,319
-66% -$46.3K ﹤0.01% 5862
2021
Q2 		$67K Buy
15,670
+3,999
+34% +$19.4K ﹤0.01% 5450
2021
Q1 		$61K Buy
11,671
+4,510
+63% +$25.8K ﹤0.01% 5718
2020
Q4 		$39K Buy
7,161
+4,160
+139% +$22.6K ﹤0.01% 5671
2020
Q3 		$25K Buy
3,001
+1,055
+54% +$9.23K ﹤0.01% 5698
2020
Q2 		$20K Buy
1,946
+1,696
+678% +$10.7K ﹤0.01% 5696
2020
Q1 		$1K Hold
250
– – ﹤0.01% 6039
2019
Q4 		$0 Sell
250
-550
-69% -$587 ﹤0.01% 6319
2019
Q3 		$1K Hold
800
– – ﹤0.01% 6248
2019
Q2 		$3K Hold
800
– – ﹤0.01% 6099
2019
Q1 		$4K Sell
800
-1,200
-60% -$5.59K ﹤0.01% 5763
2018
Q4 		$11K Sell
2,000
-800
-29% -$5.9K ﹤0.01% 5907
2018
Q3 		$38K Sell
2,800
-1,400
-33% -$14.7K ﹤0.01% 5676
2018
Q2 		$49K Buy
4,200
+800
+24% +$9.97K ﹤0.01% 5593
2018
Q1 		$38K Buy
3,400
+1,500
+79% +$13.1K ﹤0.01% 5637
2017
Q4 		$12K Hold
1,900
– – ﹤0.01% 5882
2017
Q3 		$16K Sell
1,900
-5,200
-73% -$32.5K ﹤0.01% 5763
2017
Q2 		$32K Sell
7,100
-500
-7% -$2.61K ﹤0.01% 5517
2017
Q1 		$42K Buy
7,600
+6,200
+443% +$27.1K ﹤0.01% 5503
2016
Q4 		$6K Hold
1,400
– – ﹤0.01% 5908
2016
Q3 		$9K Hold
1,400
– – ﹤0.01% 5782
2016
Q2 		$12K Buy
1,400
+600
+75% +$5.65K ﹤0.01% 5621
2016
Q1 		$7K Buy
800
+200
+33% +$1.64K ﹤0.01% 5795
2015
Q4 		$7K Hold
600
– – ﹤0.01% 5804
2015
Q3 		$7K Buy
+600
New +$8.47K ﹤0.01% 5776

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.41B AUM 41.48% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Wells Fargo's ADAP Position: Q4 2025 in Review

Wells Fargo sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 2,700 shares — an estimated $351 sold.

Wells Fargo first reported a position in ADAP in Q3 2015 and held it in 41 quarters. The position peaked at $85.6K in Q1 2024. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Wells Fargo reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wells Fargo sold 2,700 Adaptimmune Therapeutics shares in Q4 2025, an estimated $351.
  • Wells Fargo first reported a position in Adaptimmune Therapeutics in Q3 2015 and held it in 41 quarters.
  • Wells Fargo's Adaptimmune Therapeutics position peaked at $85.6K in Q1 2024.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Wells Fargo's 13F filing for Q4 2025, filed 13 Feb 2026.